American Journal of Geriatric Psychiatry最新文献_第4页

Psychedelics and Older Adults: What Do They Do Compared to Younger People? 迷幻药与老年人：与年轻人相比，他们会做些什么？

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-06-05 DOI: 10.1016/j.jagp.2024.05.010

引用次数: 0

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-06-04 DOI: 10.1016/j.jagp.2024.05.013

引用次数: 0

The Importance of Social Risk Factors for Cognitive Decline 认知能力衰退的社会风险因素的重要性

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-06-03 DOI: 10.1016/j.jagp.2024.05.011

引用次数: 0

Fear of Death, Excerpt From How to Grow Old in: Bertrand Russell. Portraits From memory: And Other essays 对死亡的恐惧》，摘自《如何在死亡中变老》：伯特兰-罗素记忆中的肖像：及其他随笔

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-06-01 DOI: 10.1016/j.jagp.2024.04.015

George S. Alexopoulos M.D.

引用次数: 0

Second Shift 第二班。

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-31 DOI: 10.1016/j.jagp.2024.05.009

Steven A. Ris

引用次数: 0

On Fisk Pond 菲斯克池塘

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-24 DOI: 10.1016/j.jagp.2024.05.008

引用次数: 0

Three Careers … and the Evolution of a Midwife to the Soul 三种职业......以及灵魂助产士的演变

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-23 DOI: 10.1016/j.jagp.2024.04.014

Jeanne Childs M.A. ((Board Certified Clinical Geriatric Chaplain))

引用次数: 0

Effects of Psychedelics in Older Adults: A Prospective Cohort Study 迷幻药对老年人的影响：前瞻性队列研究

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-19 DOI: 10.1016/j.jagp.2024.05.007

{"title":"Effects of Psychedelics in Older Adults: A Prospective Cohort Study","authors":"","doi":"10.1016/j.jagp.2024.05.007","DOIUrl":"10.1016/j.jagp.2024.05.007","url":null,"abstract":"<div><h3>Objective</h3><p>Affective symptoms such as anxiety, low mood, and loneliness are prevalent and highly debilitating symptoms among older adults (OA). Serotonergic psychedelics are currently investigated as novel interventions for affective disorders, yet little is known regarding their effects in OA. We investigated the mental health effects and psychological mechanisms of guided psychedelic group experiences in OA and a matched sample of younger adults (YA).</p></div><div><h3>Methods</h3><p>Using a prospective observational cohort design, we identified 62 OA (age ≥60 years) and 62 matched YA who completed surveys two weeks before, a day, two weeks, four weeks, and six months after a psychedelic group session. Mixed linear regression analyses were used to investigate longitudinal well-being changes, as well as baseline, acute, and post-acute predictors of change.</p></div><div><h3>Results</h3><p>OA showed post-psychedelic well-being improvements similar to matched YA. Among baseline predictors, presence of a lifetime psychiatric diagnosis was associated with greater well-being increases in OA (<em>B</em> = 6.72, p = .016 at the four-week key-endpoint). Compared to YA, acute subjective psychedelic effects were less intense in OA and did not significantly predict prospective well-being changes. However, relational experiences before and after psychedelic sessions emerged as predictors in OA (r(36) = .37,p = 0.025).</p></div><div><h3>Conclusions</h3><p>Guided psychedelic group sessions enhance well-being in OA in line with prior naturalistic and controlled studies in YA. Interestingly, acute psychedelic effects in OA are attenuated and less predictive of well-being improvements, with relational experiences related to the group setting playing a more prominent role. Our present findings call for further research on the effects of psychedelics in OA.</p></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1064748124003361/pdfft?md5=8d1af3817702998ed6462bcd0c0d6711&pid=1-s2.0-S1064748124003361-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141136468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Musical Organ and the Leaf 音乐风琴和树叶

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-17 DOI: 10.1016/j.jagp.2024.05.001

引用次数: 0

Anticonvulsants in the Treatment of Behavioral and Psychological Symptoms in Dementia: A Systematic Review 治疗痴呆症患者行为和心理症状的抗惊厥药物：系统综述

IF 4.4 2区医学

American Journal of Geriatric Psychiatry Pub Date : 2024-05-16 DOI: 10.1016/j.jagp.2024.05.004

{"title":"Anticonvulsants in the Treatment of Behavioral and Psychological Symptoms in Dementia: A Systematic Review","authors":"","doi":"10.1016/j.jagp.2024.05.004","DOIUrl":"10.1016/j.jagp.2024.05.004","url":null,"abstract":"<div><h3>Objectives</h3><p>Behavioral and psychological symptoms of dementia (BPSD) are common and impart a significant burden to patients, caregivers, and the health system. However, there are few pharmacological options for treating BPSD. We conducted a systematic review of clinical trials examining the efficacy of anticonvulsants in BPSD.</p></div><div><h3>Methods</h3><p>We searched five electronic databases through January 2023, for randomized controlled trials and systematic reviews evaluating the efficacy of non-benzodiazepine anticonvulsants for the treatment of BPSD. We used the Cochrane risk of bias tool to ascertain the risk of bias in included trials. Because statistical pooling of results using meta-analysis was not feasible, we synthesized findings using the Cochrane Synthesis Without Meta-analysis reporting guidelines.</p></div><div><h3>Results</h3><p>We identified 12 studies, including randomized controlled trials (RCTs) and 1 systematic review. Five RCTs evaluating valproic acid were synthesized by a recent Cochrane review which concluded that this drug is likely ineffective for BPSD. We extracted data from 6 trials involving 248 individuals comparing non-benzodiazepine anticonvulsants to either placebo or risperidone. Four trials (n = 97 participants) evaluated carbamazepine, only one of which demonstrated an improvement in the Brief Psychiatric Rating Scale measuring agitation, hostility, psychosis, and withdrawal/depression (effect size: 1.13; 95% confidence interval [CI]: 0.54–1.73) relative to placebo. Adverse effects were more common in patients receiving carbamazepine (20/27; 74%) relative to placebo (5/24; 21%). There is low quality evidence that oxcarbazepine is likely ineffective and that topiramate may be comparable to risperidone.</p></div><div><h3>Conclusion</h3><p>Anticonvulsants are unlikely to be effective in BPSD, although the quality of existing evidence is low.</p></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1064748124003336/pdfft?md5=5d73276dca97a5b7bae656d747dbebd5&pid=1-s2.0-S1064748124003336-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141054868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0